Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

BIOVACSAFE

Financiado

Biomarkers For Enhanced Vaccine Safety

BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine... ver más

31/08/2018

GSK Vaccines Srl

31M€

Presupuesto del proyecto: 31M€

Líder del proyecto

GlaxoSmithKline Vaccines Srl No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 18 Participantes

Financiación concedida El organismo FP6 notifico la concesión del proyecto el día 2018-08-31

0% 100%

18 Participantes

GSK Vaccines Srl

Lider

LSTM

N.D. | Participante

UNISI

N.D. | Participante

IMPERIAL COLLEGE OF SCIENCE...

N.D. | Participante

Proyectos interesantes

EUIN2015-62625 RED DE RE-CLASIFICACION MOLECULAR DE LAS ENFERMEDADES AUTOIN... 25K€ Cerrado

BIO2014-54164-R DESARROLLO ASISTIDO POR COMPUTADORA DE VACUNAS DE EPITOPOS:... 109K€ Cerrado

ImmunoChip Nano-assisted digitalizing of cancer phenotyping for immunot... 2M€ Cerrado

CTQ2012-32025 RMN Y RECONOCIMIENTO MOLECULAR. INTERACCIONES PROTEINA-CARBO... 421K€ Cerrado

BIO2014-54404-R APROXIMACIONES DE SISTEMAS A LA PREDICCION AVANZADA DE LA SE... 109K€ Cerrado

JCI-2011-10497 ESTRUCTURA Y FUNCIÓN DE PROTEÍNAS. PROTEÓMICA. BIOINFORMATIC... 96K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 77 meses Fecha Inicio: 2012-03-01
Fecha Fin: 2018-08-31

Líder del proyecto

GlaxoSmithKline Vaccines Srl

TRL 4-5

Presupuesto del proyecto 31M€

Descripción del proyecto BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveillance. A compact interlocking structure provides efficient and cost-effective goal delivery, while offering the full spectrum of functionality and capacity to match the needs for predictive biomarkers and models of inflammation/autoimmunity and clinical events classification. A Technology Core has transcriptomics, genotyping, proteomics, metabolomics and data mining, with depth and capacity to discover, validate and distribute novel biomarkers. A Models Core has a full range of ex vivo/in vivo murine, small animal and non-human primate models of inflammation and biomarker discovery, with advanced immunology and imaging. A Clinical Core has capability to safely and efficiently distribute clinical studies of vaccine immunosafety from small intensive trials to large-scale studies of adult, paediatric and other populations. A Populations Core has population-scale biobank discovery, clinical cohorts (with globalisation capability, autoimmune, chronic, inflammatory and infectious disease groups), large-scale genotyping and sequencing, and a safely accessible central database for online analyses of large datasets. A Regulatory Core with expertise to synthesise outputs to generate and disseminate classifications, guidelines, reference standards for vaccine development, and inform EFPIA activities. A Management Core with track record of successful public-private projects ensures Cores interoperate to maximise discovery - validation - application - re-discovery cycles, to deliver project goals on time, within budget, while maximising interactions with other actors (EFPIA, FDA, EMA).

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores